Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations

Genes Chromosomes and Cancer

Volumn 49, Issue 10, 2010, Pages 919-927

  Nguyen Khac, Florence ^a,b   Lesty, Claude ^a   Eclache, Virginie ^c   Couronné, Lucile ^d   Kosmider, Olivier ^e   Andrieux, Joris ^f   Collonge Rame, Marie Agnes ^g   Penther, Dominique ^h   Lafage, Marina ⁱ   Bilhou Nabera, Chrystele ^j   Chapiro, Elise ^a,b   Mozziconacci, Marie Joelle ^k   Mugneret, Francine ^l   Gachard, Nathalie ^m   Nadal, Nathalie ⁿ   Lippert, Eric ^o   Struski, Stephanie ^p   Dastugue, Nicole ^p   Cabrol, Christine ^q   Bernard, Olivier A ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d INSERM   (France)

^e CHU Cochin ^*  (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF BESANÇON   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ TIMONE HOSPITAL   (France)

^j BICÊTRE HOSPITAL   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l Laboratoire de cytogénétique   (France)

^m Laboratoire de cytogénétique   (France)

ⁿ UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p TOULOUSE UNIVERSITY HOSPITAL   (France)

^q LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROTEIN; PROTEIN TET2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFORMATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 77957868375     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20802     Document Type: Article

References (26)

1. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147.
2. Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C. 2009. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 88:1207-1213.
3. Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR. 2010. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891-2900.
4. Campbell PJ, Green AR. 2006. The myeloproliferative disorders. N Engl J Med 355:2452-2466.
5. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. 2006. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548-3555.
6. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. 2009. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901.
7. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, Dastugue N, Mugneret F, Lafage M, Gachard N, Nadal N, Bernard OA, Nguyen-Khac F. 2010. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 24:201-203.
8. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA. 2009. Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301.
9. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T. 2005. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664-2670.
10. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A, Vannucchi AM. 2009. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential throm-bocythemia myelofibrosis. Haematologica 94:144-146.
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. 2000. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207.
12. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. 2010. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115:496-499.
13. Kilpivaara O, Levine RL. 2008. JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science. Leukemia 22:1813-1817.
14. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. 2005. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 105:973-977.
15. Panani AD. 2007. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications. Cancer Lett 255:12-25.
16. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. 2008. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22:240-248.
17. Reilly JT, Wilson G, Barnett D, Watmore A, Potter A. 1994. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol 88:575-581.
18. Sanada M, Uike N, Ohyashiki K, Ozawa K, Lili W, Hangaishi A, Kanda Y, Chiba S, Kurokawa M, Omine M, Mitani K, Ogawa S. 2007. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia 21:992-997.
19. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P. 1998. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91:616-622.
20. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. 2009. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113:4171-4178.
21. Tefferi A, Vardiman JW. 2008. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22.
22. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. 2001. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113:763-771.
23. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. 2005. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 131:320-328.
24. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. 2009. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-911.
25. Viguie F, Aboura A, Bouscary D, Ramond S, Delmer A, Tachdjian G, Marie JP, Casadevall N. 2005. Common 4q24 deletion in four cases of hematopoietic malignancy: Early stem cell involvement? Leukemia 19:1411-1415.
26. Wang L, Ogawa S, Hangaishi A, Qiao Y, Hosoya N, Nanya Y, Ohyashiki K, Mizoguchi H, Hirai H. 2003. Molecular characterization of the recurrent unbalanced translocation der(1;7) (q10;p10). Blood 102:2597-2604.